NEWS

UK
GLOBAL

Real-World Data Show Abbott’s FreeStyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Abbott today announced new data from two real-world studies1, 2 showing people with Type 2 diabetes using GLP-1 medicines and FreeStyle Libre technology together had greater improvement in their HbA1c when compared to those treated with GLP-1 medicines only.

Abbott introduces first ever consumer biowearable, Lingo™, set to re-energise the nation

Abbott today announced it is introducing Lingo™ across the UK -- a pioneering biowearable device and app designed to help people improve their overall health and wellbeing.

New Real-World Data Shows Abbott’s FreeStyle Libre® Technology Delivers Significant Health Benefits For People with Type 2 Diabetes

Real-world comparative study in Sweden shows that FreeStyle Libre system use is associated with lower HbA1c levels for people with Type 2 diabetes using insulin therapy.

New Update to Abbott’s FreeStyle LibreLink App Enables People Using FreeStyle Libre® 2 System to Receive Automatic Glucose Readings Every Minute

Abbott has today announced an update to its FreeStyle LibreLink app, which will allow people who use the FreeStyle Libre 2 system to get real-time minute-by-minute glucose readings automatically displayed on the app.

Over A Third Of Brits In The Dark Over When Antibiotics Are Needed, New Abbott Survey Reveals

A new survey from global healthcare company, Abbott, has found that over a third (37%) of Brits either don’t know or are misinformed as to what illnesses antibiotics can effectively treat.

Brits Living with Diabetes Feel Stigma and Bias Impact Their Ability to Manage Their Condition

With diabetes prevalence expected to reach almost 5.5 million across the UK by 2030 , new results from a first-of-its-kind survey by Abbott has identified a clear disconnect between the perceptions of the British public and those living with diabetes when it comes to stigma surrounding the condition.

Abbott Launches New Integrated Digital Solution for People with Diabetes in the UK

Nov. 9, 2022 – Abbott today announced its FreeStyle LibreLink app is now compatible with Novo Nordisk’s smart connected insulin pens in the UK, which will help reduce the burden associated with diabetes management and personalise care for thousands of people living with diabetes

The UK’s First Remote Neuromodulation Patient-Care Technology From Abbott Now Available In Key Centres Across Country

3 Nov 2022 – Abbott’s NeuroSphere™ Virtual Clinic, The UK’s first remote neuromodulation patient-care technology, is now available in six specialist centres across the UK; Bristol, Glasgow, Kent and Canterbury, Leeds, Oxford and Southampton.

New Data Shows That Abbott’s FreeStyle Libre® System Reduces Diabetes-related Hospitalisations for People with Type 2 Diabetes on Once-daily Insulin Therapy

Abbott today announced new data from the Real World Evidence of FreeStyle Libre (RELIEF) study showing the use of the FreeStyle Libre continuous glucose monitoring system (CGM) significantly reduced the rate of hospitalisations due to acute diabetes events (ADEs) for people living with type 2 diabetes on once-daily (basal) insulin therapy.

New Analysis Shows That Abbott’s Freestyle® Libre System Provides Similar And Sustained Reductions In Glucose Levels For People With Both Type 1 And Type 2 Diabetes

29th April, 2020 — Abbott announced today it received CE Mark to the IVD Directive (98/79/EC) for its laboratory-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had the novel coronavirus (COVID-19).

ABBOTT, CAMDIAB AND YPSOMED UNVEIL NEW AUTOMATED INSULIN DELIVERY PARTNERSHIP FOR PEOPLE WITH DIABETES

29th April, 2020 — Abbott announced today it received CE Mark to the IVD Directive (98/79/EC) for its laboratory-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had the novel coronavirus (COVID-19).

Modern glucose measurement with the smallest and thinnest sensor in the world: Abbott's FreeStyle Libre 3 now available for use in the UK

Abbott, the global healthcare company, today announced that its FreeStyle Libre 3 continuous glucose monitoring (CGM) system, the latest addition to the world-leading FreeStyle Libre sensor technology, is now available for use in the UK.

Abbott Achieves CE Mark for the First Rapid Handheld Blood Plasma Test for Concussions

Abbott has achieved CE Mark for the i-STAT TBI Plasma test, the first rapid handheld traumatic brain injury (TBI) blood plasma test, which permits marketing in the European Union and will help clinicians assess individuals with suspected mild TBIs, including concussions.

Abbott Receives CE Mark for First Widely Available Lab-based Blood Test for Traumatic Brain Injury, Increasing Access to Concussion Evaluation

Abbott has received CE Mark for a laboratory traumatic brain injury (TBI) blood test, which will be the first widely available and will help clinicians assess individuals with suspected mild TBIs, including concussions. The test will run on Abbott’s Alinity™ i laboratory instrument, which produces a result within 18 minutes.

Abbott Introduces NeuroSphere Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the UK

Airborne illnesses beyond COVID-19 and influenza must be part of prevention strategies in care homes to reduce hospitalisation of residents this winter, according to healthcare company Abbott.

Robust Testing for Airborne Illnesses Urged Across the Care Industry this Winter to Protect Residents and Staff

Airborne illnesses beyond COVID-19 and influenza must be part of prevention strategies in care homes to reduce hospitalisation of residents this winter, according to healthcare company Abbott.

Real-World Data Show Abbott's FreeStyle LibreLink App Users Spend More Time in Target Glucose Range Compared to Reader Users

Abbott this week announced new data recently published in the Journal of Diabetes Science and Technology demonstrating that people living with diabetes who use FreeStyle Libre's smartphone app (versus a reader) experienced an average 5% (approximately an hour per day) more time spent in the target glucose range, known as Time in Range (TIR).

Abbott's Panbio™ Rapid Antigen Self-Test Receives CE Mark, Increasing Access to Fast, Reliable COVID-19 Testing in the United Kingdom

Abbott announced today it has received CE Mark for its Panbio™ COVID-19 Antigen Self-Test for sale direct-to-consumers for use in the detection of the SARS-CoV-2 virus in adults and children with or without symptoms. The approval paves the way for critical access to fast, reliable self-testing throughout the United Kingdom (UK) and Europe to reduce the spread of infection as economies reopen and daily life activities resume.

Abbott's Panbio™ Rapid Antigen Test Now Has a CE Mark for Use on Children; First Rapid Antigen Test with Performance Data on Children

Abbott announced today it now has a CE Mark for use of its Panbio™ COVID-19 Ag Rapid Test Device to detect the SARS-COV-2 virus in children age 15 years and younger. The CE Mark is based on the first-ever study focused on the performance of a rapid antigen test on children, including infants.

Abbott's New Coronary Imaging Platform Powered by Artificial Intelligence Launches in Europe

Abbott today announced that its new imaging platform powered by Ultreon 1.0 Software, is now CE Marked in Europe.

Abbott Announces its Pandemic Defence Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Future Pandemics, Currently Searching for COVID-19 Variants

We've launched the Abbott Pandemic Defense Coalition, aiming to help prevent viral threats from reaching pandemic levels and identify new COVID-19 variants.

Abbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure

A large group known as HIV controllers has been identified by Abbott Virus Hunters in the Democratic Republic of Congo. They may help us understand natural HIV suppression.

Research Reveals Mental Health Impact on Families of Childhood Diabetes Diagnosis

Abbott today releases findings of two research surveys, undertaken before and during the COVID-19 pandemic, examining how a childhood Type 1 diabetes (T1D) diagnosis affects the emotional and mental health of children and their families. The research also reveals the impact of managing the condition with the added pressure of the COVID-19 outbreak.

Abbott Donates 10,000 Additional FreeStyle Libre Sensors for UK Hospital Patients with Diabetes During COVID-19 Pandemic Peak

Abbott announced today that it will donate a further 10,000 FreeStyle Libre sensors to support patients with diabetes who use insulin and are admitted to UK hospitals during the COVID-19 pandemic. NHS Trusts can now make applications directly to Abbott to access this allocation of the world’s leading1 sensor-based glucose monitoring technology.

Abbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab

Abbott announced today it has received CE Mark for two new uses of its Panbio™ COVID-19 Ag Rapid Test Device for the detection of the SARS-CoV-2 virus: asymptomatic testing and self-swabbing.

Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test

Abbott has received CE Mark for its new quantitative SARS-CoV-2 IgG (Immunoglobulin G) lab-based serology test.

Abbott Obtains CE Mark for Laboratory PCR Assay That Detects SARS-CoV-2, Flu A, Flu B, and RSV in One Test

Abbott announced CE Mark for the company's Alinity™ m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) in one test.

Abbott Secures Three Leading UK Workplace Accolades Including Top 10 Best Workplace For Women in 2020

Global healthcare leader Abbott has been awarded three prestigious accolades reflecting its working culture and commitment to UK employees, including ranking in Britain's top 10 Best Workplace for Women for 2020.

Abbott's FreeStyle® Libre 3 System Receives CE Mark – Features World's Smallest, Thinnest Sensor with Best-in- Class Performance at the Same Low Cost for People with Diabetes

Abbott, the worldwide leader in continuous glucose monitoring (CGM) technology, announced today it has secured CE Mark (Conformité Européenne) for its next-generation FreeStyle Libre 3 system, which is now approved for use by people living with diabetes in Europe.

Statement from Abbott on use of Abbott’s Architect SARS-CoV-2 antibody test with home kits

27th May, 2020 — We understand we live in unprecedented times, where the demand for self-sample collection solutions for testing is high, but Abbott has not currently validated our SARS-CoV-2 laboratory tests for self-sample collection procedures, such as finger stick (capilliary) blood.

Abbott Announces Contract to Supply Millions of IgG Lab-based Antibody Tests to the UK Government

21st May, 2020 — Abbott announced a government contract to supply millions of its laboratory-based IgG antibody tests to NHS laboratories across the UK over the coming months. Abbott has already shipped 800,000 antibody tests this week to NHS laboratories, to be used as part of the testing initiative announced by the Secretary of State for Health today.

Abbott Announces CE Mark and Immediate Availability of its COVID-19 Laboratory-Based Antibody Test

29th April, 2020 — Abbott announced today it received CE Mark to the IVD Directive (98/79/EC) for its laboratory-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had the novel coronavirus (COVID-19).

SHOWING 1 - 6 OF 32

32

6

© 2024 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.